New drug duo tested for Tough-to-Treat lung cancer
NCT ID NCT02496663
Summary
This early-stage trial is testing the safety and best dose of a two-drug combination for people with a specific type of advanced lung cancer. The study is for adults whose EGFR-mutant non-small cell lung cancer has continued to grow despite prior targeted therapy. Researchers want to see if giving the drugs osimertinib (a pill) and necitumumab (an IV infusion) together is safe and tolerable.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke Cancer Center Cary
Cary, North Carolina, 27518, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Stanford Cancer Institute Palo Alto
Palo Alto, California, 94304, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania, 15232, United States
Conditions
Explore the condition pages connected to this study.